Matica Biotechnology, a specialized contract development and manufacturing organization (CDMO) for cell and gene therapies (CGT), has entered into a strategic partnership with the National Center for Therapeutics Manufacturing (NCTM), part of the Texas A&M Engineering Experiment Station, to provide a comprehensive, end-to-end service platform that supports CGT developers from early research through IND submission, clinical development, and commercialization.

By combining NCTM’s early-stage research and development capabilities with Matica Bio’s advanced manufacturing and regulatory expertise, the partnership offers a seamless solution for innovators in the CGT space—all within College Station, Texas.

“This partnership creates a unique synergy between academic innovation and industrial execution,” said Paul Kim, Chief Executive Officer of Matica Biotechnology. “By combining NCTM’s early discovery and development support with Matica Bio’s clinical and commercial manufacturing capabilities, we’re creating a powerful ecosystem that reduces costly barriers for CGT innovators.”

“This collaboration exemplifies our mission to bridge academia and industry,” said Dr. Baley Reeves, Director of the NCTM. “By aligning with Matica Biotechnology, we’re expanding opportunities for translational research and accelerating the delivery of cutting-edge therapies to patients in need.”

The integrated offering is expected to reduce development timelines, cost, enhance production efficiency, and streamline the path to market for next-generation therapies—empowering researchers and biotech companies to bring transformative treatments to patients faster.